| orvepitant (GW 823296) / NeRRe Therap |
2014-003947-36: Study to evaluate the efficacy of the drug orvepitant at one dose level (30 mg every day) to reduce the urge to cough in patients suffering from chronic (long-term) cough that is resistant to treatment. This means all the patients on the study will receive orvepitant (it is an ‘open-label’ trial), so they and the Investigator will know they are taking the investigational medication. |
|
|
| Ongoing | 2 | 15 | Europe | Orvepitant, GW823296, Tablet | NeRRe Therapeutics Ltd, NeRRe Therapeutics Ltd | Chronic treatment-refractory cough, Chronic cough, Diseases [C] - Symptoms and general pathology [C23] | | | | |
2016-004979-49: A study to assess the efficacy and safety of three doses of orvepitant in subjects with chronic refractory cough |
|
|
| Not yet recruiting | 2 | 292 | Europe | Orvepitant, Film-coated tablet | NeRRe Therapeutics Ltd., NeRRe Therapeutics Ltd. | Chronic Refractory Cough, Chronic Refractory Cough, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-006278-22: A study to find out if orvepitant is safe to use and reduces the severity of cough in patients with idiopathic pulmonary fibrosis Een onderzoek om erachter te komen of orvepitant veilig is voor gebruik en de ernst van het hoesten vermindert bij patiënten met idiopathische longfibrose |
|
|
| Not yet recruiting | 2 | 108 | Europe | Orvepitant, Film-coated tablet | NeRRe Therapeutics Ltd, NeRRe Therapeutics Ltd | Chronic cough in patients with idiopathic pulmonary fibrosis, Chronic cough in patients with lung fibrosis of unknown cause, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
IPF COMFORT, NCT05185089: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| Completed | 2 | 80 | Europe, US | Orvepitant Maleate, Placebo | Nerre Therapeutics Ltd., Pharm-Olam International | Cough, Idiopathic Pulmonary Fibrosis | 06/24 | 06/24 | | |
